Loading clinical trials...
Loading clinical trials...
A Phase III Multi-national, Multi-centre, Open Label, Safety Study to Assess the Safety of Chronic Therapy With the Humanised Anti-TNF PEG Conjugate CDP870 400 mg sc, (Dosed 4-weekly), in the Treatment of Patients With Active Crohn's Disease Who Have Previously Completed Studies CDP870-031 or CDP870-032
Conditions
Interventions
Certolizumab Pegol (CDP870)
Locations
206
United States
45102
Birmingham, Alabama, United States
45028
Huntsville, Alabama, United States
45144
Tucson, Arizona, United States
45095
Orange, California, United States
45006
San Diego, California, United States
45131
San Diego, California, United States
Start Date
July 1, 2004
Primary Completion Date
August 1, 2012
Completion Date
August 1, 2012
Last Updated
August 1, 2018
NCT06226883
NCT07184931
NCT06918808
NCT06647615
NCT07377188
NCT07385131
Lead Sponsor
UCB Pharma SA
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions